AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32130178 — intervention group
Group type: EXPERIMENTAL
Intervention: HealthMindr app (intervention arm)
Number of subjects: 657
Study 32130178 — intervention group
Group type: COMPARATOR
Intervention: HealthMindr app (control arm)
Number of subjects: 657
Study 32130186 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-day Brush Day & Night intervention
Number of subjects: 20
Study 32130186 — intervention group
Group type: COMPARATOR
Intervention: Control group (free toothpaste and toothbrushes)
Number of subjects: 20
Study 32130192 — intervention group
Group type: EXPERIMENTAL
Intervention: Outsmart HPV content on the Web with monthly unidirectional vaccination reminders sent via text messages
Number of subjects: 1995
Study 32130192 — intervention group
Group type: EXPERIMENTAL
Intervention: Outsmart HPV content on the Web with monthly interactive vaccination reminders sent via text messages
Number of subjects: 1995
Study 32130192 — intervention group
Group type: COMPARATOR
Intervention: Standard information on the Web about HPV vaccine
Number of subjects: 1995
Study 32130196 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP mobile messaging intervention (interactive text messages over 4 weeks)
Number of subjects: 66
Study 32130196 — intervention group
Group type: COMPARATOR
Intervention: Enhanced standard of care (ESC)
Number of subjects: 66
Study 32130199 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinematographic recordings of lumbar spine motion during maximum flexion and extension
Number of subjects: 11
Study 32130406 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD-negative group
Number of subjects: 65
Study 32130406 — intervention group
Group type: COMPARATOR
Intervention: MRD-positive group
Number of subjects: 65
Study 32130814 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined biopsy
Number of subjects: 2103
Study 32130814 — intervention group
Group type: COMPARATOR
Intervention: MRI-targeted biopsy
Number of subjects: 2103
Study 32130814 — intervention group
Group type: COMPARATOR
Intervention: Systematic biopsy
Number of subjects: 2103
Study 32130813 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of bedaquiline, pretomanid, and linezolid
Number of subjects: 109
Study 32130813 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 109
Study 32131045 — intervention group
Group type: EXPERIMENTAL
Intervention: Online health diary program (SMARTLog) with dynamic feedback, users completed 61 or more SMARTLogs (n=25, 33% of the sample)
Number of subjects: 76
Study 32131045 — intervention group
Group type: EXPERIMENTAL
Intervention: Online health diary program (SMARTLog) with dynamic feedback, users generated 11 or more new SMARTProfiles (n=23, 30% of the sample)
Number of subjects: 76
Study 32131045 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative number of SMARTLogs completed
Number of subjects: 76
Study 32131045 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative number of SMARTProfiles received
Number of subjects: 76
Study 32131056 — intervention group
Group type: EXPERIMENTAL
Intervention: Argus I implant
Number of subjects: 1
Study 32131056 — intervention group
Group type: EXPERIMENTAL
Intervention: Argus II implant
Number of subjects: 1
Study 32131687 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Number of subjects: 2237
Study 32131742 — intervention group
Group type: EXPERIMENTAL
Intervention: Renally inappropriate medications (RIMs)
Number of subjects: 556
Study 32131742 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentially inappropriate medications (PIMs)
Number of subjects: 556
Study 32131742 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors and allopurinol
Number of subjects: 556
Study 32131742 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific medications identified for deprescription
Number of subjects: 556
Study 32131842 — intervention group
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (400, 600, and up to 800 U)
Number of subjects: 155
Study 32131847 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 1462
Study 32131847 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing moderate-to-vigorous physical activity (MVPA)
Number of subjects: 1462
Study 32131847 — intervention group
Group type: EXPERIMENTAL
Intervention: Substituting sedentary time (ST) with light intensity physical activity (LIPA)
Number of subjects: 1462
Study 32131878 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled alterations in ET O2 and CO2 levels during mechanical ventilation
Number of subjects: 0
Study 32131878 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related responses to controlled alterations in ET gas tensions
Number of subjects: 0
Study 32131882 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality indicators for structure and process
Number of subjects: 2006
Study 32131882 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality indicators for outcome
Number of subjects: 2006
Study 32131882 — intervention group
Group type: EXPERIMENTAL
Intervention: Between-centre variation
Number of subjects: 2006
Study 32131882 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical uncertainty of outcome indicators
Number of subjects: 2006
Study 32131901 — intervention group
Group type: EXPERIMENTAL
Intervention: Snoring occurring for ≥ 3 months
Number of subjects: 1578
Study 32131901 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 1578
Study 32131901 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 1578
Study 32131901 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 1578
Study 32131901 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillar hypertrophy
Number of subjects: 1578
Study 32131901 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoid hypertrophy
Number of subjects: 1578
Study 32133329 — intervention group
Group type: EXPERIMENTAL
Intervention: Nusinersen treatment
Number of subjects: 39
Study 32133329 — intervention group
Group type: COMPARATOR
Intervention: Palliative care practices
Number of subjects: 39
Study 32133329 — intervention group
Group type: COMPARATOR
Intervention: Overall patient management
Number of subjects: 39
Study 32133329 — intervention group
Group type: COMPARATOR
Intervention: Mortality
Number of subjects: 39
Study 32133329 — intervention group
Group type: COMPARATOR
Intervention: Enteral nutrition
Number of subjects: 39
Study 32133329 — intervention group
Group type: COMPARATOR
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 39
Study 32133329 — intervention group
Group type: COMPARATOR
Intervention: Sedative treatment
Number of subjects: 39
Study 32134216 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutch Leakage Score (DLS)
Number of subjects: 1546
Study 32134216 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 1546
Study 32134216 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT)
Number of subjects: 1546
Study 32134216 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of positive PCT, CRP, and DLS values
Number of subjects: 1546
Study 32134216 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of negative PCT, CRP, and DLS values
Number of subjects: 1546
Study 32134216 — intervention group
Group type: EXPERIMENTAL
Intervention: Morbidity
Number of subjects: 1546
Study 32134216 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 1546
Study 32134933 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with POI
Number of subjects: 123
Study 32134978 — intervention group
Group type: EXPERIMENTAL
Intervention: SRD5A2 promoter methylation in CRPC samples
Number of subjects: 90
Study 32134978 — intervention group
Group type: EXPERIMENTAL
Intervention: SRD5A2 methylation (whole promoter region)
Number of subjects: 90
Study 32134978 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypermethylation of specific regions (nucleotides -434 to -4)
Number of subjects: 90
Study 32134978 — intervention group
Group type: EXPERIMENTAL
Intervention: SRD5A2 methylation (specific region)
Number of subjects: 90
Study 32135121 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR T cells
Number of subjects: 0
Study 32135121 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 32135566 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygotes for p.Thr789Ala(C)
Number of subjects: 219
Study 32135566 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygotes for p.Thr1381Ala(C)
Number of subjects: 219
Study 32135566 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygotes for p.Gln852Arg(C)
Number of subjects: 219
Study 32135566 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygotes for both p.Thr789Ala(C) and p.Gln852Arg(T)
Number of subjects: 219
Study 32135566 — intervention group
Group type: EXPERIMENTAL
Intervention: Carriers of two copies of the p.Thr1381Ala(T)/p.Gln852Arg(T) haplotype
Number of subjects: 219
Study 32138529 — intervention group
Group type: EXPERIMENTAL
Intervention: MViV (mitral valve-in-valve)
Number of subjects: 903
Study 32138529 — intervention group
Group type: COMPARATOR
Intervention: MViR (mitral valve-in-ring)
Number of subjects: 903
Study 32138529 — intervention group
Group type: COMPARATOR
Intervention: ViMAC (valve-in-mitral annular calcification)
Number of subjects: 903
Study 32138529 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (MViV, MViR, ViMAC)
Number of subjects: 903
Study 32138691 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-12 Mental Health Score (MCS)
Number of subjects: 5022
Study 32138691 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-12 Physical Health Score (PCS)
Number of subjects: 5022
Study 32138691 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective HRQoL
Number of subjects: 5022
Study 32138734 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents with obesity
Number of subjects: 431
Study 32138734 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents with extreme obesity
Number of subjects: 431
Study 32138734 — intervention group
Group type: EXPERIMENTAL
Intervention: General findings
Number of subjects: 431
Study 32138781 — intervention group
Group type: EXPERIMENTAL
Intervention: ASAC-LS
Number of subjects: 17
Study 32138781 — intervention group
Group type: COMPARATOR
Intervention: APAC
Number of subjects: 17
Study 32138938 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician Affective Reactivity Index (CL-ARI)
Number of subjects: 98
Study 32138941 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure-based cognitive-behavioral therapy (CBT)
Number of subjects: 1
Study 32139144 — intervention group
Group type: EXPERIMENTAL
Intervention: Accidental awareness during general anaesthesia (AAGA) detection using three repetitions of standardised direct questioning over 30 days.
Number of subjects: 2015
Study 32139144 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured interviews to verify memories during general anaesthesia.
Number of subjects: 2015
Study 32139144 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative data collection on general anaesthesia conduct for all participants.
Number of subjects: 2015
Study 32139220 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized thienopyridine treatment for patients with loss-of-function (LOF) alleles (class 2, n = 272)
Number of subjects: 1445
Study 32139220 — intervention group
Group type: COMPARATOR
Intervention: Wild-type genotype or gain-of-function allele (class 1, n = 1,118)
Number of subjects: 1445
Study 32139298 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib + Selumetinib
Number of subjects: 77
Study 32139298 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib + Savolitinib
Number of subjects: 77
Study 32139298 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib + Durvalumab
Number of subjects: 77
Study 32140080 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT + CHMF
Number of subjects: 233
Study 32140080 — intervention group
Group type: COMPARATOR
Intervention: ACT + placebo
Number of subjects: 233
Study 32140113 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the nucleus accumbens
Number of subjects: 1
Study 32140610 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted Diabetes Self-Management Education intervention
Number of subjects: 221
Study 32140610 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 221
Study 32140672 — intervention group
Group type: EXPERIMENTAL
Intervention: MD1003 (300 mg/day)
Number of subjects: 30
Study 32140672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 32140727 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fat ingestion
Number of subjects: 40
Study 32140727 — intervention group
Group type: COMPARATOR
Intervention: Lean control subjects
Number of subjects: 40
Study 32140912 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled or nasal corticosteroids
Number of subjects: 12
Study 32140912 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A4 inhibitors
Number of subjects: 12
Study 32140912 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A4 inhibitors (specific corticosteroid: beclomethasone)
Number of subjects: 12
Study 32140912 — intervention group
Group type: COMPARATOR
Intervention: Normal morning plasma cortisol
Number of subjects: 12
Study 32142375 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 0
Study 32142532 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus XELOX or mFOLFOX6 (Phase-A)
Number of subjects: 128
Study 32142532 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus FOLFIRI (Phase-B)
Number of subjects: 128
Study 32142960 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanoparticle burden in amniotic fluids
Number of subjects: 100
Study 32142960 — intervention group
Group type: EXPERIMENTAL
Intervention: Fraction containing nanoparticles and ions
Number of subjects: 100
Study 32142960 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with potential sources of exposure
Number of subjects: 100
Study 32142960 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall nanoparticle concentrations
Number of subjects: 100
Study 32143580 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical response evaluation (CRE-1) using endoscopy with bite-on-bite biopsies
Number of subjects: 0
Study 32143580 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical response evaluation (CRE-2) using PET-CT, endoscopy with bite-on-bite biopsies, and EUS with fine-needle aspiration (FNA)
Number of subjects: 0
Study 32143580 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of major locoregional residual disease (> 10% residual carcinoma or any residual nodal disease)
Number of subjects: 0
Study 32143585 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide stress test (FST)
Number of subjects: 84
Study 32143664 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula therapy at 20, 40, and 60 L/min
Number of subjects: 24
Study 32143664 — intervention group
Group type: COMPARATOR
Intervention: Baseline (conventional oxygen therapy)
Number of subjects: 24
Study 32143777 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory art-based activity at the MMFA (2.3 h once a week for 12 weeks)
Number of subjects: 130
Study 32143921 — intervention group
Group type: EXPERIMENTAL
Intervention: ACHD patients
Number of subjects: 67
Study 32143921 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 67
Study 32143921 — intervention group
Group type: EXPERIMENTAL
Intervention: ACHD patients with cerebral abnormalities
Number of subjects: 67
Study 32144134 — intervention group
Group type: EXPERIMENTAL
Intervention: Utomilumab (0.03-10.0 mg/kg every 4 weeks) plus Rituximab (375 mg/m2)
Number of subjects: 67
Study 32144134 — intervention group
Group type: EXPERIMENTAL
Intervention: Utomilumab plus Rituximab
Number of subjects: 67
Study 32145771 — intervention group
Group type: EXPERIMENTAL
Intervention: Enasidenib (60-300 mg per day, oral, in repeated 28-day treatment cycles)
Number of subjects: 17
Study 32146304 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib 5 mg orally twice daily
Number of subjects: 44
Study 32146703 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZES) treatment
Number of subjects: 62
Study 32147213 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral delivery of plasmid encoding IL-12 (tavokinogene telseplasmid; tavo), 0.5 mg/ml followed by electroporation (six pulses, 1500 V/cm) on days 1, 5, and 8 every 90 days
Number of subjects: 46
Study 32147669 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib (15 mg) plus PD-0325901 (6 mg)
Number of subjects: 41
Study 32147671 — intervention group
Group type: EXPERIMENTAL
Intervention: Buparlisib (80 mg) in combination with imatinib (400 mg)
Number of subjects: 60
Study 32147671 — intervention group
Group type: COMPARATOR
Intervention: Control (standard therapies)
Number of subjects: 60
Study 32147973 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional connectivity (FC) of sgACC-DLPFC
Number of subjects: 88
Study 32147973 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional connectivity (FC) of pgACC-DLPFC
Number of subjects: 88
Study 32147973 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical efficacy associated with DLPFC-sgACC functional connectivity
Number of subjects: 88
Study 32148099 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived Stress
Number of subjects: 162
Study 32148099 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive Symptoms in Patients
Number of subjects: 162
Study 32148099 — intervention group
Group type: COMPARATOR
Intervention: Decisional Conflict Scale
Number of subjects: 162
Study 32148332 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-point discrimination threshold (TPDT) over the affected shoulder of patients with FS
Number of subjects: 38
Study 32148332 — intervention group
Group type: EXPERIMENTAL
Intervention: Left/right judgment task (LRJT) performance in patients with FS
Number of subjects: 38
Study 32148332 — intervention group
Group type: COMPARATOR
Intervention: TPDT and LRJT performance in patients with FS compared to healthy controls
Number of subjects: 38
Study 32149736 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone
Number of subjects: 0
Study 32149736 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 0
Study 32149760 — intervention group
Group type: EXPERIMENTAL
Intervention: No-reflow group
Number of subjects: 59
Study 32149760 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 59
Study 32149760 — intervention group
Group type: EXPERIMENTAL
Intervention: Before nicorandil medication
Number of subjects: 59
Study 32150040 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted hysterectomy
Number of subjects: 18
Study 32150040 — intervention group
Group type: COMPARATOR
Intervention: Open laparotomy technique
Number of subjects: 18
Study 32150040 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 18
Study 32150070 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathological evaluation of unallocated pancreas organs
Number of subjects: 100
Study 32150070 — intervention group
Group type: EXPERIMENTAL
Intervention: Macroscopic assessment by transplant surgeons
Number of subjects: 100
Study 32150314 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessed by Kansas City Cardiomyopathy Questionnaire and Minnesota Living with Heart Failure Questionnaire
Number of subjects: 408
Study 32150314 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal aerobic capacity (peak oxygen consumption)
Number of subjects: 408
Study 32150314 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal exercise capacity (6-min walk distance)
Number of subjects: 408
Study 32150314 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume of daily activity (accelerometry)
Number of subjects: 408
Study 32150314 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-estimated functional class
Number of subjects: 408
Study 32150314 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting echocardiography
Number of subjects: 408
Study 32150314 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma natriuretic peptide levels
Number of subjects: 408
Study 32151245 — intervention group
Group type: EXPERIMENTAL
Intervention: TELSA programme (Type 1 Diabetes Education in Lifestyle and Self Adjustment)
Number of subjects: 13000
Study 32151247 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antihyperglycemic agents with a blood glucose cut-off value of 3.9 mmol/L (70 mg/dL)
Number of subjects: 94
Study 32151247 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antihyperglycemic agents with a blood glucose cut-off value of 3.0 mmol/L (54 mg/dL)
Number of subjects: 94
Study 32151247 — intervention group
Group type: COMPARATOR
Intervention: Sulfonylurea therapy
Number of subjects: 94
Study 32151332 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbapenemase-producing Enterobacterales
Number of subjects: 1040
Study 32151332 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-carbapenemase-producing Enterobacterales
Number of subjects: 1040
Study 32151332 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconfirmed CRE
Number of subjects: 1040
Study 32151790 — intervention group
Group type: EXPERIMENTAL
Intervention: IOERT (11.1 Gy) followed by HWBI (40.5 Gy in 15 fractions)
Number of subjects: 583
Study 32152017 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKAs)
Number of subjects: 3082
Study 32152017 — intervention group
Group type: COMPARATOR
Intervention: Direct oral anticoagulants (DOACs)
Number of subjects: 3082
Study 32152153 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma shared decision-making (SDM) intervention
Number of subjects: 10
Study 32152160 — intervention group
Group type: EXPERIMENTAL
Intervention: Early biomarkers (albuminuria, N-acetyl-beta-D-glucosaminidase, kidney injury molecule-1, neutrophil gelatinase-associated lipocalin)
Number of subjects: 0
Study 32152160 — intervention group
Group type: EXPERIMENTAL
Intervention: Predisposition biomarkers (GM2AP, transferrin, t-gelsolin)
Number of subjects: 0
Study 32152160 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 0
Study 32152168 — intervention group
Group type: EXPERIMENTAL
Intervention: French-LARS score (adapted LARS scale)
Number of subjects: 1000
Study 32152168 — intervention group
Group type: EXPERIMENTAL
Intervention: French-LARS score
Number of subjects: 1000